136 related articles for article (PubMed ID: 26725729)
1. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Li D; Moughan J; Crane C; Hoffman JP; Regine WF; Abrams RA; Safran H; Liu C; Chang P; Freedman GM; Winter KA; Guha C; Abbruzzese JL
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):554-60. PubMed ID: 26725729
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
Li D; Frazier M; Evans DB; Hess KR; Crane CH; Jiao L; Abbruzzese JL
J Clin Oncol; 2006 Apr; 24(11):1720-8. PubMed ID: 16520463
[TBL] [Abstract][Full Text] [Related]
3. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Abrams RA; Winter KA; Regine WF; Safran H; Hoffman JP; Lustig R; Konski AA; Benson AB; Macdonald JS; Rich TA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):809-16. PubMed ID: 21277694
[TBL] [Abstract][Full Text] [Related]
4. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
5. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
9. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
11. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
12. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
13. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
Hattangadi JA; Hong TS; Yeap BY; Mamon HJ
Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088
[TBL] [Abstract][Full Text] [Related]
14. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.
Tanaka M; Okazaki T; Suzuki H; Abbruzzese JL; Li D
Cancer; 2011 Feb; 117(4):744-51. PubMed ID: 20922799
[TBL] [Abstract][Full Text] [Related]
15. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Li D; Liu H; Jiao L; Chang DZ; Beinart G; Wolff RA; Evans DB; Hassan MM; Abbruzzese JL
Cancer Res; 2006 Mar; 66(6):3323-30. PubMed ID: 16540687
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML
Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]